Repligen Corp vs. REGENXBIO Inc.
Repligen Corp (RGEN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| RGEN | RGNX | |
|---|---|---|
| Market Cap | $10.25 billion | $531.74 million |
| Revenue (TTM) | $785.10 million | $174.48 million |
| Net Income (TTM) | $41.54 million | $-196,432,000 |
RGEN leads on 3 of 3 size & scale factors.
Valuation
| RGEN | RGNX | |
|---|---|---|
| P/E Ratio | 248.89 | — |
| Price / Book | 4.85 | 7.41 |
| Price / Sales | 13.06 | 3.05 |
RGEN and RGNX split the valuation factors evenly.
Profitability
| RGEN | RGNX | |
|---|---|---|
| Net Margin | 5.29% | -112.58% |
| Return on Equity | 1.97% | -273.72% |
RGEN leads on 2 of 2 profitability factors.
Risk & Sentiment
| RGEN | RGNX | |
|---|---|---|
| Short Interest | 7.13% | 1.96% |
RGNX leads on 1 of 1 risk & sentiment factors.
Dig deeper: RGEN overview, RGEN financials, RGNX overview, RGNX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.